Skip to main content
VivoSim Labs, INC. logo

VivoSim Labs, INC. — Investor Relations & Filings

Ticker · VIVS ISIN · US68620A2033 US Professional, scientific and technical activities
Open in API
Filings indexed 790 across all filing types
Latest filing 2019-06-03 Annual Report
Country US United States of America
Listing US VIVS

About VivoSim Labs, INC.

https://organovo.com/

VivoSim Labs, Inc. is a biotechnology services company that develops and utilizes bioprinted, three-dimensional (3D) human tissues designed to emulate human biology and disease. The company provides testing services for drugs and drug candidates, primarily for the pharmaceutical and biotechnology sectors. VivoSim Labs specializes in offering liver and intestinal toxicology insights through its proprietary New Approach Methodologies (NAMs), including its NAMkind™ 3D models. These non-animal testing platforms are used to generate human-relevant safety and toxicology data early in the drug discovery and development process, aiming to provide insights before animal studies or clinical trials.

Recent filings

Filing Released Lang Actions
10-K
Annual Report FY 2019
2019-06-03 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated May 22, 2019, reporting the issuance of a press release announcing preliminary financial results for the fiscal fourth quarter and year ended March 31, 2019. The text explicitly states that the press release is attached as Exhibit 99.1 and incorporated by reference, and that the information is not "filed" for purposes of Section 18 of the Exchange Act. The document itself does not contain detailed financial statements or substantive financial data but rather announces the release of such information. The document length is 3635 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, according to the "Menu vs Meal" rule, this document is an announcement of financial results, not the results themselves. The appropriate classification is Regulatory Filings (RNS), as it is a general regulatory announcement and does not fit other specific categories like Earnings Release (ER) or Interim Report (IR).
2019-05-22 English
FORM 4 SUBMISSION
Director's Dealing
2019-05-20 English
FORM 4 SUBMISSION
Director's Dealing
2019-05-20 English
FORM 4 SUBMISSION
Director's Dealing
2019-05-20 English
FORM 4 SUBMISSION
Director's Dealing
2019-05-20 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.